Results 151 to 160 of about 14,264,655 (329)

Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective A better understanding of factors associated with multiple sclerosis (MS) disease activity and disability is needed. Given the strong link between comorbid depression and MS disease activity and disability, we aimed to determine whether the depression genetic burden, as modelled using its polygenic score, is associated with MS disease ...
Ali Manouchehrinia, Kathryn C. Fitzgerald, Amber Salter, Ruth Ann Marrie, Lars Alfredsson, Charles N. Bernstein, James M. Bolton, Gary Cutter, John D. Fisk, Lesley A. Graff, Carol A. Hitchon, Jan Hillert, Ingrid Kockum, Yi Lu, Fred D. Lublin, Kyla McKay, Tomas Olsson, Scott Patten, Amit Patki, Hayley Riel, Klementy Shchetynsky, Pernilla Stridh, Hemant K. Tiwari, Jerry S. Wolinsky, Kaarina Kowalec   +24 more
wiley   +1 more source

n-3 PUFAs for depression: treatment effect or absence-of-placebo effect? [PDF]

Transl Psychiatry, 2022
Memarpouri A, van der Does W, Molendijk ML.   +2 more
europepmc   +1 more source

Adjunctive Thrombolytics After Successful Endovascular Reperfusion: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Annals of Neurology, EarlyView.
Objective The efficacy and safety of intra‐arterial thrombolysis (IAT) as an adjunct to endovascular thrombectomy (EVT) in large vessel occlusion strokes (LVOS) remain uncertain, with recent randomized controlled trials (RCTs) yielding conflicting results.
Mohamed F. Doheim, Mahmoud H. Mohammaden, Ammar Jumah, Qingwu Yang, Wenjie Zi, Yangmei Chen, Yamei Tang, Yajie Liu, Xiaochuan Huo, Liping Liu, Bernard Yan, Zhongrong Miao, Wei Hu, Chunrong Tao, Xinfeng Liu, Liqun Jiao, Xuesong Bai, Wenhuo Chen, Diogo C. Haussen, Thanh Nguyen, Raul G. Nogueira   +20 more
wiley   +1 more source

Editorial: Placebo Effect in Pain and Pain Treatment. [PDF]

Front Pain Res (Lausanne), 2022
Bernstein MH, Blease C, Vase L.
europepmc   +1 more source

The Effect of Maternal Supplementation with Linoleic and .GAMMA.-Linolenic Acids on the Fat Composition and Content of Human Milk: A Placebo-Controlled Trial.

, 1991
Andrew J. Cant, Janet Shay, David F. Horrobin   +2 more
openalex   +2 more sources

Various “faces” of the placebo-effect [PDF]

, 1998
N. Lurina, Д И Шустов, A. Hovrachyov, A. Borozdin, S.A. Shustova   +4 more
openalex   +1 more source

Placebo and placebo effects in medicine [PDF]

Journal of the Royal Society of Medicine, 2000
Michael Emmans Dean, Joseph S Conway
openaire   +2 more sources

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis

Annals of Neurology, EarlyView.
Objective Tofersen is the first effective and approved therapy for superoxide dismutase 1 (SOD1)‐associated amyotrophic lateral sclerosis (ALS [SOD1‐ALS]). Following treatment with tofersen, neurofilament levels in patients' cerebrospinal fluid (CSF) and serum seem to respond earlier than clinical parameters.
Christina Steffke, Karthik Baskar, Franziska Bachhuber, Maximilian Wiesenfarth, Johannes Dorst, Joachim Schuster, Florian Schöberl, Peter Reilich, Martin Regensburger, Alexander German, René Günther, Maximilian Vidovic, Susanne Petri, Thomas Meyer, Tim Hagenacker, Julian Grosskreutz, Ute Weyen, Patrick Weydt, Thomas Haarmeier, Paul Lingor, Joachim Wolf, Andreas Hermann, Johannes Prudlo, Kornelia Günther, Antje Knehr, Zeynep Elmas, Zeljko Uzelac, Simon Witzel, Wolfgang Philipp Ruf, Axel Freischmidt, Ritchie Ho, Albert C. Ludolph, Jochen H. Weishaupt, Hayrettin Tumani, Patrick Oeckl, David Brenner, Alberto Catanese   +36 more
wiley   +1 more source

Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study [PDF]

, 2000
J Szkudlarek
openalex   +1 more source

Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas

Annals of Neurology, EarlyView.
Objective Mitogen‐activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
D. Christine Noordhoek, David F. Hanff, Pim J. French, Sarah A. van Dijk, Erik A.C. Wiemer, Olivier C. Manintveld, Martin J. van den Bent, Walter Taal   +7 more
wiley   +1 more source